ArticleFrontiers in public health2023
Clinical and immunological characteristics of HIV/syphilis co-infected patients following long-term antiretroviral treatment.
Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Ocular Syphilis in the Era of Resurgence: Clinical Characteristics and Diagnostic Challenges in a Single-Center Cohort.Medicina (Kaunas, Lithuania) · 2026Article
- Penicillin or Ceftriaxone for Neurosyphilis in People With HIV: A Retrospective, Propensity Score-Matched Multicenter Study in Mexico.Open forum infectious diseases · 2026Article
- Syphilis Co-Infection Among People Living with HIV in Romania: Epidemiological and Clinical Characteristics in a Single-Center Retrospective Study.Pathogens (Basel, Switzerland) · 2026Article
- Multidisciplinary management of severe odontogenic maxillofacial multi-space infection in a patient with HIV-syphilis coinfection and advanced immunosuppression: a case report.Frontiers in cellular and infection microbiology · 2026Article
- Factors associated with cerebrospinal fluid abnormalities suggestive of neurosyphilis in HIV-negative patients with secondary syphilis: a retrospective study.Frontiers in medicine · 2026Article
- Analysis of influencing factors for syphilis serofast and development and evaluation of a predictive model.Frontiers in immunology · 2026Article
- The Association Between Syphilis Infection and HIV Acquisition and HIV Disease Progression in Sub-Saharan Africa.Tropical medicine and infectious disease · 2025Article
- The Rise of Syphilis Infections and Reinfections over a Decade (2009-2019) in the Bolognese Area: A Retrospective Analysis.Microorganisms · 2025Article
- Research Advances in Clinical Strategies and Preclinical Models for Syphilis Relapse.Infection and drug resistance · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to analyze the efficacy of anti-syphilis treatment and the impact of syphilis events on HIV virology and immunology in HIV/syphilis co-infected patients on long-term antiretroviral therapy (ART) and to investigate the incidence and factors of syphilis recurrence/re-infection/serofast state. The insights derived from this investigation can potentially guide strategies for preventing and managing syphilis and AIDS. Methods: A retrospective case-control study was conducted at the AIDS clinic of Peking Union Medical College Hospital from January 2003 to December 2022. The study involved 86 HIV/syphilis co-infected patients and 86 HIV mono-infected patients matched based on age, baseline CD4 + T cell counts, and viral load. We examined the clinical characteristics of HIV/syphilis co-infected patients, evaluated the efficacy of anti-syphilis treatment, and analyzed the dynamic changes in HIV virology and immunology. The Generalized Estimating Equations (GEE) model investigated the factors associated with HIV/syphilis co-infection and syphilis recurrence/reinfection/serofast state. Results: Syphilis serofast state was observed in 11.6% (10/86) of HIV/syphilis co-infected patients after treatment, and 33.7% (29/86) had syphilis recurrence or re-infection. The overall effectiveness of syphilis treatment stood at 76.8% (63/82). Notably, the effectiveness of syphilis treatment displayed a significant correlation with baseline syphilis titers exceeding 1:128 ( Conclusion: While HIV/syphilis co-infected patients typically receive adequate treatment, the incidence of syphilis recurrence and reinfection remain notably elevated. A heightened HLA-DR + CD8+/CD8+ % is a notable risk factor for HIV/syphilis co-infection and syphilis recurrence/reinfection/serofast state. Therefore, it is advisable to reinforce health education efforts and ensure regular follow-ups for people living with HIV undergoing ART to monitor syphilis infection or increased risk of syphilis infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.